A pharmaceutical company is a business that discovers, develops, manufactures, and sells medications. These companies range from massive global corporations with tens of billions in annual revenue to small startups focused on a single experimental treatment. Their core business revolves around turning scientific research into products that treat, prevent, or diagnose disease, then navigating a lengthy regulatory process to bring those products to market.
What Pharmaceutical Companies Actually Do
The work of a pharmaceutical company spans the entire life of a drug, from early laboratory research through manufacturing and sales. The process starts with scientists identifying a biological target, like a protein involved in a disease, and then searching for a chemical compound that can interact with that target in a useful way. This discovery phase feeds into years of testing, first in lab settings and animals, then in progressively larger groups of human volunteers.
Research and development is the engine of the business. Major companies invest heavily: Merck spent more than $9.4 billion on R&D in just a five-year stretch between 1996 and 2000, and spending has only grown since. Bristol-Myers Squibb has historically put more than 10% of total sales back into R&D. That investment is a gamble. Most drug candidates fail, and the revenue from a successful product has to cover not only its own development costs but also the cost of every project that never made it to market.
Beyond R&D, pharmaceutical companies run large-scale manufacturing operations to produce drugs at consistent quality, manage global supply chains, and maintain sales and marketing teams that work with healthcare providers. They also handle regulatory submissions, post-market safety monitoring, and legal protection of their intellectual property.
Types of Pharmaceutical Companies
Not all pharmaceutical companies look the same. The industry divides roughly into three categories, each with a different business model and culture.
- Large pharmaceutical (“Big Pharma”) companies are global corporations with diversified drug portfolios spanning multiple disease areas. Johnson & Johnson, the largest by revenue, brought in $88.8 billion in 2024. Roche ($65.3 billion), Merck ($64.2 billion), Pfizer ($63.6 billion), and AbbVie ($56.3 billion) round out the top five. These companies have the resources to run dozens of clinical trials simultaneously and sell products in countries worldwide.
- Biotechnology companies use living organisms or biological systems to develop treatments, often focusing on complex diseases like cancer or rare genetic conditions. They tend to be smaller, more entrepreneurial, and more narrowly focused than traditional pharma. Companies like Amgen, Gilead, and Biogen fall into this category, though the line between biotech and pharma has blurred as the two increasingly overlap.
- Generic manufacturers produce copies of brand-name drugs after patent protection expires. A generic drug contains the same active ingredient and works the same way in the body as the original. Health regulators require generics to meet the same standards, which is why they can be sold at a fraction of the price: the manufacturer doesn’t need to repeat the expensive discovery and testing process.
How a Drug Gets to Market
Bringing a new drug from the lab to your pharmacy is one of the longest, most expensive processes in any industry. It traditionally takes 10 to 15 years and, when you factor in the cost of failed projects plus the capital tied up over that time, averages around $879 million per successful drug. That figure varies wildly by specialty: anti-infective drugs average closer to $379 million, while pain medications can exceed $1.7 billion.
The process follows a structured path. It begins with discovery and development in the laboratory, where researchers identify promising compounds. Next comes preclinical research, where those compounds are tested in lab and animal studies to answer basic safety questions. Only after clearing these hurdles does a drug enter clinical research, the phase where it’s tested in people.
Clinical trials unfold in stages. Early trials use small groups of volunteers to assess safety and dosing. Mid-stage trials expand to larger groups to evaluate whether the drug actually works. Late-stage trials test the drug in hundreds or thousands of patients to confirm effectiveness and monitor side effects across a broader population. The FDA generally expects results from two well-designed clinical trials before considering approval, though for rare diseases, convincing evidence from one trial can be enough.
Regulatory Approval and Oversight
Before any drug can be sold in the United States, it must be reviewed and approved by the FDA’s Center for Drug Evaluation and Research. The review weighs whether a drug’s health benefits outweigh its known risks for the people it’s intended to treat. Reviewers examine the clinical trial data, consider what other treatments already exist for the condition, and evaluate how risks can be managed through labeling and monitoring.
Approval isn’t the end of oversight. Some drugs require ongoing risk management plans after they reach the market. And for therapies that receive accelerated approval, a faster pathway reserved for serious or life-threatening conditions, the company must continue running studies to confirm the drug’s benefit. If those follow-up studies fail, the FDA can pull the drug from the market.
Outside the U.S., other regulatory bodies perform similar functions. The European Medicines Agency handles approvals for the European Union, and each major market has its own agency. A pharmaceutical company selling globally may need to navigate dozens of separate regulatory processes.
How Pharmaceutical Companies Make Money
Direct drug sales are the primary revenue source, but how companies price those drugs depends on the market. A drug for a rare condition affecting a small number of patients will carry a high price tag per dose, because the total patient pool is limited. A drug for a common condition like allergies can be priced lower because it will sell in enormous volume. Both strategies aim at the same goal: recovering the massive upfront investment in R&D.
Companies also generate revenue through licensing and partnership deals. A smaller company that discovers a promising compound but lacks the resources to run global clinical trials might license the rights to a larger company. These deals typically include an upfront payment, milestone payments triggered by events like completing a trial phase or receiving FDA approval, and ongoing royalties calculated as a percentage of future sales. Some arrangements involve profit-sharing, where both parties split the net earnings from a product rather than just sales revenue.
Patents and Market Exclusivity
The pharmaceutical business model depends on intellectual property protection. When a company develops a new drug, it obtains a patent, which lasts 20 years from the filing date. Because patents are often filed early in development, the actual period of market protection after a drug is approved and available for sale is typically much shorter, often 10 to 12 years or less.
Separate from patents, the FDA grants periods of market exclusivity that prevent competitors from gaining approval for equivalent products. A new chemical entity receives five years of exclusivity. Orphan drugs, those developed for rare diseases, get seven years. Pediatric exclusivity adds six months to existing protections when a company conducts studies in children. These windows give companies a limited period to sell their drug without generic competition, which is when they earn back their development costs and generate profit.
Once both the patent and exclusivity periods expire, generic manufacturers can enter the market with lower-cost versions. This is why drug prices often drop significantly after generics become available.
AI and the Changing Drug Discovery Process
Artificial intelligence is reshaping how pharmaceutical companies find and develop new drugs. Traditional drug discovery is sequential and slow: identify a target, screen thousands of compounds, optimize the best candidates, then test them. AI can compress the earliest stages dramatically by processing vast amounts of biological and chemical data simultaneously.
The results so far are striking. Insilico Medicine identified a new drug target for a lung scarring disease and advanced a candidate into preclinical testing in 18 months, a process that normally takes four to six years, at a fraction of the usual cost. Exscientia developed an AI-designed molecule for obsessive-compulsive disorder in under 12 months, making it the first AI-designed drug to enter human clinical trials. A review of 173 studies found that AI integration consistently accelerated various stages of the development pipeline.
Major pharmaceutical companies are investing heavily in these capabilities. Sanofi signed a $1.2 billion partnership with Exscientia to use AI for discovering cancer and immune system therapies. Other companies are building in-house AI platforms or partnering with technology firms that combine automated lab testing with machine learning to identify new uses for existing molecules. While AI won’t eliminate the need for clinical trials or regulatory review, it has the potential to lower the cost and failure rate of early drug development significantly.